RCM
BIO icon

Raleigh Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Raleigh Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6
Closed -$1.67K – 628
2026
Q1 		$1.67K Buy
+6
New +$1.73K ﹤0.01% 562
2025
Q1 		– Sell
-6
Closed -$1.97K – 627
2024
Q4 		$1.97K Sell
6
-6
-50% -$2.04K ﹤0.01% 837
2024
Q3 		$4.01K Buy
12
+5
+71% +$1.59K ﹤0.01% 730
2024
Q2 		$1.91K Buy
7
+4
+133% +$1.16K ﹤0.01% 788
2024
Q1 		$1.04K Buy
3
+2
+200% +$658 ﹤0.01% 842
2023
Q4 		$323 Buy
+1
New +$313 ﹤0.01% 1027
2023
Q2 		– Sell
-81
Closed -$38.8K – 846
2023
Q1 		$38.8K Buy
81
+47
+138% +$22K 0.02% 277
2022
Q4 		$14.3K Buy
34
+22
+183% +$8.88K 0.01% 372
2022
Q3 		$5K Buy
+12
New +$5.98K ﹤0.01% 473

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Raleigh Capital Management's BIO Position: Q2 2026 in Review

Raleigh Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2026, closing a stake of 6 shares — an estimated $1.67K sold.

Raleigh Capital Management first reported a position in BIO in Q3 2022 and held it in 9 quarters. The position peaked at $38.8K in Q1 2023. 400 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Raleigh Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q2 2026 after selling out during the quarter.
  • Raleigh Capital Management sold 6 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $1.67K.
  • Raleigh Capital Management first reported a position in Bio-Rad Laboratories Class A in Q3 2022 and held it in 9 quarters.
  • Raleigh Capital Management's Bio-Rad Laboratories Class A position peaked at $38.8K in Q1 2023.
  • 400 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Raleigh Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.